Pronatural

GSK (formerly GlaxoSmithKline plc) is a global biopharmaceutical company headquartered in London, United Kingdom, with a rich heritage dating back to 1715. The company's core purpose is to unite science, technology, and talent to get ahead of disease, focusing on the discovery, development, manufacture, and marketing of innovative medicines and vaccines. Core Business and Strategy In July 2022, GSK underwent a significant transformation by separating its Consumer Healthcare business (which included brands like Sensodyne and Voltaren) into an independent, listed company named Haleon. This strategic move allowed GSK to concentrate solely on its biopharmaceuticals segment. GSK's operations are now focused on four core therapeutic areas: Respiratory, Immunology, and Inflammation: Developing treatments for conditions like asthma and COPD, and targeting fibrotic lung, liver, and kidney diseases. Oncology: Focusing on treatments for blood and women's cancers, utilizing precision medicine to match the right treatment to the right patient. HIV: A leader in HIV treatment and prevention through its majority-owned specialist company, ViiV Healthcare, which is exclusively dedicated to ending the HIV epidemic. Infectious Diseases: Offering one of the broadest portfolios of vaccines and medicines to prevent and treat various infections, including meningitis, shingles, hepatitis, and seasonal influenza. Key Products and Global Reach The EANs provided (which have UK/Spanish prefixes) correspond to a range of GSK's pharmaceutical products, typically prescription medicines and vaccines, rather than consumer goods. GSK products include a broad range of general medicines for bacterial infections, skin conditions, and respiratory ailments. The company's historic and current products feature several drugs listed on the World Health Organization's List of Essential Medicines, such as amoxicillin and zidovudine. GSK operates in more than 80 countries, sells products in 122 markets, and has a global network of manufacturing and R&D sites.